Boenning & Scattergood Portfolio holdings
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Developed Markets ETF
VEA
|
+$2.41M |
| 2 |
CVS Health
CVS
|
+$1.67M |
| 3 |
Wells Fargo
WFC
|
+$1.58M |
| 4 |
Target
TGT
|
+$1.34M |
| 5 |
AbbVie
ABBV
|
+$1.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
UHT
Universal Health Realty Income Trust
UHT
|
+$5.13M |
| 2 |
iShares Biotechnology ETF
IBB
|
+$1.13M |
| 3 |
GSK
GSK
|
+$934K |
| 4 |
KL
Kirkland Lake Gold Ltd Ordinary
KL
|
+$732K |
| 5 |
General Motors
GM
|
+$713K |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.34% |
| 2 | Technology | 13% |
| 3 | Industrials | 10.2% |
| 4 | Financials | 9.85% |
| 5 | Energy | 8.69% |
Similar funds
Boenning & Scattergood's Q1 2019 Portfolio in Review
As of Q1 2019, Boenning & Scattergood held 289 positions worth $334M, up 17% from $287M the previous quarter. Its ten largest holdings account for 24% of the portfolio.
Boenning & Scattergood deployed $13.4M of net new capital in Q1 2019, opening 27 new positions and adding to 129 existing holdings. Its largest new stake was Target: 18,390 shares worth $1.48M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, down from 17% a quarter earlier, followed by Technology and Industrials.
On the sell side, the largest reduction was Universal Health Realty Income Trust, an estimated $5.13M trimmed.
- Boenning & Scattergood's largest Q1 2019 buy was Target: 18,390 shares worth $1.48M.
- Boenning & Scattergood added most to Vanguard FTSE Developed Markets ETF in Q1 2019, an estimated $2.41M increase.
- Boenning & Scattergood's biggest Q1 2019 reduction was Universal Health Realty Income Trust, cutting an estimated $5.13M.
- Boenning & Scattergood fully exited iShares Biotechnology ETF in Q1 2019, selling an estimated $1.13M.
- Boenning & Scattergood's ten largest holdings make up 24% of its $334M portfolio in Q1 2019.
- Boenning & Scattergood opened 27 new positions and closed 9 in Q1 2019.
- Boenning & Scattergood's portfolio value rose 17% quarter-over-quarter to $334M.
Based on Boenning & Scattergood's 13F filing for Q1 2019, filed 22 Apr 2019.